<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Annals of Clinical and Experimental Neurology</journal-id><journal-title-group><journal-title xml:lang="en">Annals of Clinical and Experimental Neurology</journal-title><trans-title-group xml:lang="ru"><trans-title>Анналы клинической и экспериментальной неврологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2075-5473</issn><issn publication-format="electronic">2409-2533</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">452</article-id><article-id pub-id-type="doi">10.17816/psaic452</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Unknown</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Intravenous thrombolysis in acute ischemic stroke</article-title><trans-title-group xml:lang="ru"><trans-title>Системный медикаментозный тромболизис в острейшем периоде ишемического инсульта</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Domashenko</surname><given-names>M. A.</given-names></name><name xml:lang="ru"><surname>Домашенко</surname><given-names>M. A.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>mdomashenko@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7682-6672</contrib-id><name-alternatives><name xml:lang="en"><surname>Maksimova</surname><given-names>Marina Yu.</given-names></name><name xml:lang="ru"><surname>Максимова</surname><given-names>Марина Юрьевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>mdomashenko@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kistenev</surname><given-names>B. А.</given-names></name><name xml:lang="ru"><surname>Кистенев</surname><given-names>Б. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>mdomashenko@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Loskutnikov</surname><given-names>M. A.</given-names></name><name xml:lang="ru"><surname>Лоскутников</surname><given-names>M. A.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>mdomashenko@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5539-245X</contrib-id><name-alternatives><name xml:lang="en"><surname>Konovalov</surname><given-names>Rodion N.</given-names></name><name xml:lang="ru"><surname>Коновалов</surname><given-names>Родион Николаевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Med.), senior researcher, Neuroradiology department</p></bio><bio xml:lang="ru"><p>к.м.н., с.н.с. отд. лучевой диагностики</p></bio><email>mdomashenko@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Bryukhov</surname><given-names>V. V.</given-names></name><name xml:lang="ru"><surname>Брюхов</surname><given-names>Василий Валерьевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>mdomashenko@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3820-4554</contrib-id><name-alternatives><name xml:lang="en"><surname>Krotenkova</surname><given-names>Marina V.</given-names></name><name xml:lang="ru"><surname>Кротенкова</surname><given-names>Марина Викторовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>D. Sci. (Med.), Head, Radiology department</p></bio><bio xml:lang="ru"><p>д.м.н., зав. отд. нейровизуализации</p></bio><email>mdomashenko@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Suslina</surname><given-names>Z. A.</given-names></name><name xml:lang="ru"><surname>Суслина</surname><given-names>Зинаида Александровна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>mdomashenko@gmail.com</email><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Research Center of Neurology</institution></aff><aff><institution xml:lang="ru">ФГБНУ «Научный центр неврологии»</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Research Centre of Neurology</institution></aff><aff><institution xml:lang="ru">ФГБНУ «Научный центр неврологии»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2008-06-14" publication-format="electronic"><day>14</day><month>06</month><year>2008</year></pub-date><volume>2</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>5</fpage><lpage>12</lpage><history><date date-type="received" iso-8601-date="2017-02-14"><day>14</day><month>02</month><year>2017</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2008, Domashenko M.A., Maksimova M.Y., Kistenev B.А., Loskutnikov M.A., Konovalov R.N., Bryukhov V.V., Krotenkova M.V., Suslina Z.A.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2008, Domashenko M.A., Maksimova M.Y., Kistenev B.А., Loskutnikov M.A., Konovalov R.N., Bryukhov V.V., Krotenkova M.V., Suslina Z.A.</copyright-statement><copyright-year>2008</copyright-year><copyright-holder xml:lang="en">Domashenko M.A., Maksimova M.Y., Kistenev B.А., Loskutnikov M.A., Konovalov R.N., Bryukhov V.V., Krotenkova M.V., Suslina Z.A.</copyright-holder><copyright-holder xml:lang="ru">Domashenko M.A., Maksimova M.Y., Kistenev B.А., Loskutnikov M.A., Konovalov R.N., Bryukhov V.V., Krotenkova M.V., Suslina Z.A.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://annaly-nevrologii.com/pathID/article/view/452">https://annaly-nevrologii.com/pathID/article/view/452</self-uri><abstract xml:lang="en"><p>Strategic trend in the treatment of acute stroke resulted from thrombosis or embolization of intracerebral arteries is reperfusion of the blood flow in the ischemic area – thrombolysis. The modern methods of neuroimaging (CT and MR-angiography, diffusion and perfusion-weighted MRI, CT perfusion) play an important role in the thrombolysis decision making, as they allow to visualize the occlusion of the artery causing acute stroke, recanalization of the artery due to thrombolytic therapy, as well as the dynamics of the blood flow and metabolism in the respective brain regions. The presented clinical examples demonstrate the high efficacy of the thrombolytic treatment in acute ischemic stroke under the condition of absolute compliance with the inclusion and exclusion criteria to this therapy. The treatment of patients with acute stroke should be guided by the principles of evidence-based medicine and rely on adequate diagnostic algorithm of neuroimaging methods.</p></abstract><trans-abstract xml:lang="ru"><p>тратегическим направлением в лечении острых нарушений мозгового кровообращения, развившихся на фоне тромбозов и эмболий внутримозговых сосудов, является восстановление (реперфузия) нарушенного кровотока в зоне ишемии – тромболизис. Современные методы нейровизуализации (КТ- и МР-ангиография, диффузионно- и перфузионно-взвешенная МРТ, КТ-перфузия) играют ключевую роль в принятии решения о медикаметозном тромболизисе, поскольку они позволяют объективизировать окклюзию артерии, приведшую к развитию острого инсульта, достигнутую в процессе тромболизиса реканализацию, а также динамику состояния кровотока и метаболизма в соответствующих отделах мозга. Приведенные в качестве иллюстрации клинические наблюдения демонстрируют высокую эффективность тромболитической терапии в острейшем периоде ишемического инсульта при условии абсолютного соблюдения показаний и противопоказаний для данного вида лечения. Ведение пациента в течение острого периода инсульта должно быть основано на данных доказательной медицины и опираться на адекватный диагностический алгоритм применения инструментальных методов исследования.</p></trans-abstract><kwd-group xml:lang="en"><kwd>ischemic stroke</kwd><kwd>thrombolysis</kwd><kwd>neuroimaging</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>ишемический инсульт</kwd><kwd>тромболизис</kwd><kwd>нейровизуализация</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Суслина З.А., Танашян М.М., Ионова В.Г. Ишемический инсульт: кровь, сосудистая стенка, антитромботическая терапия. М.: Мед. книга, 2005.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Adams H., del Zoppo G., Alberts M. et al. Guidelines for the management of adults with ischemic stroke. Stroke 2007; 38; 1655–1711.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Barber P.A., Darby D.G., Desmond P.M. at al. Prediction of stroke outcome with echoplanar perfusion and diffusion weighted MRI. Neurology 1998; 51: 418–426.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Clark W.M. Recombinant tissue type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: A randomized controlled trial. JAMA 1999; 282: 2019–2026.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Fagan S.C., Morgenstern L.B., Petitta A. еt al. Cost effectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rttPA Stroke Study Group. Neurology 1998; 50: 883–890.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Hacke W., Donnan G., Fieshi C. et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rttPA stroke trials. Lancet 2004; 363: 768–774.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Hacke W., Kaste M., Fieschi C. et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995; 274: 1017–1025.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Hacke W., Kaste M., Fieschi C. et al. Randomized double blind placebo controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 1998; 352 (9136): 1245–1251.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Otsuka Y., Fukuyama H. CT criteria for thrombolysis in acute ischemic stroke. Nippon Rinsho 2006; 64 (Suppl. 7): 336–340.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Schellinger P.D., Jansen O., Fiebach J.B. Monitoring intravenous recombinant tissue plasminogen activator thrombolysis for acute ischemic stroke with diffusion and perfusion MRI. Stroke 2000; 31:1318–1328.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>The National Institute of Neurological Disorders and Stroke rttPA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N. Engl. J. Med. 1995; 333: 1581–1587.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Tomalla G., Sobesky J., Kohrmann M. еt al. Two tales: hemorrhagic transformation but not parenchymal hemorrhage after thrombolysis is related to severity and duration of ischemia: MRI study of acute stroke patients treated with intravenous tissue plasminogen activator within 6 hours. Stroke 2007; 38: 313–318.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Wahlgren N., Ahmad N., Davalos A. et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in StrokeeMonitoring Study (SISTTMOST): an observaa tional study. Lancet 2007; 369: 275–282.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Wardlaw C., Wardlaw J. Therapeutic thrombolysis for acute ischaemic stroke. BMJ 2003; 326: 233–234.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Wardlaw J.M., Zoppo G., Yamaguchi T. et al. Trombolysis for acute ischaemic stroke. Cochrane Database Syst. Rev. 2000; 2: CD 000213.</mixed-citation></ref></ref-list></back></article>
